Genetic polymorphism in pathogenesis of irritable bowel syndrome
- PMID: 25548468
- PMCID: PMC4273120
- DOI: 10.3748/wjg.v20.i47.17693
Genetic polymorphism in pathogenesis of irritable bowel syndrome
Abstract
Irritable bowel syndrome (IBS) is a complex symptom-based disorder without established biomarkers or putative pathophysiology. IBS is a common functional gastrointestinal disorder which is defined as recurrent abdominal pain or discomfort that has at least two of the following symptoms for 3 d per month in the past 3 mo according to ROME III: relief by defecation, onset associated with a change in stool frequency or onset with change in appearance or form of stool. Recent discoveries revealed genetic polymorphisms in specific cytokines and neuropeptides may possibly influence the frequencies and severity of symptoms, as well as the therapeutic responses in treating IBS patients. This review gives new insights on how genetic determinations influence in clinical manifestations, treatment responses and potential biomarkers of IBS.
Keywords: Cytokines; Endocannabinoids; Genetic polymorphism; Irritable bowel syndrome; Psychiatric distress; Serotonin.
References
-
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491. - PubMed
-
- Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15:237–241. - PubMed
-
- Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;21:663–676. - PubMed
-
- Curzon G. Serotonin and appetite. Ann N Y Acad Sci. 1990;600:521–530; discussion 530-531. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
